• PDF / 171,195 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 40 Downloads / 166 Views

DOWNLOAD

REPORT

---

1 S

Influenza A (H1N1) infection, anxiety and sinus tachycardia: 2 case reports A 23-year-old woman developed Influenza A (H1N1) infection during treatment with amsacrine, cyclophosphamide, cytarabine and fludarabine, and a 26-year-old man developed anxiety and sinus tachycardia during treatment with oseltamivir. Case 1: The woman had acute myeloblastic leukaemia and had undergone allogeneic hematopoietic stem cell transplantation (AHSCT) from an HLA fully matched cousin. However, seven months after transplantation, she was hospitalised with pancytopenia. Hence, she was scheduled for second transplantation from another HLA fully matched cousin. Prior to second transplantation, she developed sinusitis that was treated with levofloxacin and febrile neutropenia treated with cefoperazone/sulbactam and amikacin. At the time of febrile neutropenia, her blood culture was positive for E. coli and cefoperazone/sulbactam was switched to imipenem. Prior to transplantation, she also developed herpes labialis and received treatment with valaciclovir. Her antifungal prophylaxis was switched from fluconazole to posaconazole. Nine days prior to transplantation, she was non-febrile. In December 2009, she underwent second AHSCT transplantation following the FLAMSA regimen, which included amsacrine, cyclophosphamide, cytarabine and fludarabine [routes and dosages not stated]. On day 6 post transplantation, she developed fever and cough. Her PCR test was positive for H1N1 [duration of treatment to reaction onset not stated]. Therefore, treatment with oseltamivir was initiated. Thoracic high-resolution CT was repeated and the findings were consistent with fungal infection. Treatment with posaconazole was discontinued and she was started on amphotericin B liposomal therapy. Her fever remained in control for 6 days, but recurred on the same day of neutrophil engraftment. Due to persistent cough, treatment with oseltamivir was continued for additional 5 days. By day 16 post-transplantation, her fever was in control and cough reduced. Case 2: The man had acute myeloblastic leukaemia and underwent AHSCT from an unrelated donor in July 2009. Following the transplantation, he developed cytomegalovirus infection twice that was treated with ganciclovir. His unspecified immunosuppressive therapy was discontinued, four months after transplantation. His medical history was significant for disseminated fungal infection (Trichosporon) and continued to receive voriconazole post-transplantation, which was later discontinued. Six months after transplantation, in January 2010, he was hospitalised due to fever, cough and pancytopenia. Treatment with piperacillin/tazobactam, oseltamivir 75mg BID [route not stated] and voriconazole was initiated. He underwent various investigation and was diagnosed with influenza A (H1N1) infection. Additionally, thoracic high-resolution CT scan was consistent with viral and fungal pneumonia. He continued to receive treatment with piperacillin/tazobactam, oseltamivir and voriconazole. However, oseltamivir was switched to